ライフサイエンスコーパス: 5-HT receptor

1 on by autocrine signalling through the SER-7 5-HT receptor.

2 uptake transporter (SERT) and 15 subtypes of 5-HT receptor.

3 tor antagonist, which has no effect on other 5-HT receptor.

4 ments of the pallidum, which express several 5-HT receptors.

5 erived MC (huMC) expressed mRNA for multiple 5-HT receptors.

6 ) for the 5-HT(2) receptor relative to other 5-HT receptors.

7 that control the activity of the prefrontal 5-HT receptors.

8 ffects are mediated by at least 14 different 5-HT receptors.

9 nigra which in turn is mediated via multiple 5-HT receptors.

10 pine is an antagonist of all five Drosophila 5-HT receptors.

11 o ligands directly interacting with specific 5-HT receptors.

12 onin (5-HT) system, including alterations in 5-HT receptors.

13 its actions via ionotropic and metabotropic 5-HT receptors.

14 ors of the 5-HT transporter and a variety of 5-HT receptors.

15 in animals containing null alleles of these 5-HT receptors.

16 nd olfaction through at least four different 5-HT receptors.

17 specially animals expressing only individual 5-HT receptors.

18 n (5-HT), which subsequently act on multiple 5-HT receptors.

19 -hydroxytryptamine(2A) (5-HT(2A)) serotonin (5-HT) receptor.

20 receptor is the least understood serotonin (5-HT) receptor.

21 n SMC growth and Rho A/ROCK participation in 5-HT receptor 1B/1D-mediated mitogenesis of vascular SMC

22 Ile (INI) of serotonin [5-hydroxytryptamine (5-HT)] receptor 2C (5-HT(2C)R) with Val, Gly, and Val (V

23 the serotonin receptor 5-hydroxytryptamine (5-HT) receptor 5-HT2AR.

24 The distribution of the serotonin (5-HT) receptor 5-HT2C mRNA was examined at the single-ce

25 yptamine (5-HT)) led to sequestration of the 5-HT receptor (5-HT2AR) into a Rab11-positive juxtanucle

26 , in vivo atlas of four of the human brain's 5-HT receptors (5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4) and t

27 onin (5-HT) interacts with a wide variety of 5-HT receptors (5-HTR) of which 5-HT2AR plays an importa

28 ription and translation for each of the five 5-HT receptors (5-HTRs) to identify neurons, based on ce

29 Serotonin (5-hydroxytryptamine, 5-HT) receptors (5-HTRs) play critical roles in brain an

30 were given ketanserin (an antagonist of the 5-HT receptor, 5-HT(2A)) or scopolamine (an antagonist o

31 tis elegans encodes a new type of ionotropic 5-HT receptor, a 5-HT-gated chloride channel.

32 ing antagonists for the 5-hydroxytryptamine (5-HT) receptor, about 50% of patients given moderately e

33 however, the specific combination of DA and 5-HT receptors activated determined the regional- and ce

34 e tested the hypothesis that episodic spinal 5-HT receptor activation (without AIH) is sufficient to

35 ause of this effect is through inhibition of 5-HT receptor activation by quinine, as we observed here

36 Thus, episodic spinal 5-HT receptor activation is sufficient to elicit pMF by

37 at the facilitation of TRPV1 by metabotropic 5-HT receptor activation may contribute to hypersensitiv

38 Since 5-HT receptor activation stimulates NADPH oxidase activi

39 he effect of serotonin (5-hydroxytryptamine, 5-HT) receptor activation on segmental and descending mo

40 othesis that serotonin [5-hydroxytryptamine (5-HT)] receptor activation enhances TRPV1 function in mo

41 (ketanserin tartrate), and the non-selective 5-HT receptor agents, 2-(1-piperazinyl)quinoline dimalea

42 Responses to 5-HT receptor agonist challenge were assessed by local c

43 .5, 1.0, or 4.0 microg/0.5 microl/side), the 5-HT receptor agonist EMD 386088 (at 0.0, 1.0, and 4.0 m

44 5-HT and 5-HT receptor agonists depressed the firing rate of both

45 he possibility that hepatic-targeted 5-HT or 5-HT receptor agonists might reduce postprandial hypergl

46 l experiments examined the impact of various 5-HT receptor agonists on NPY stimulated eating and alte

47 The influence of 5-HT receptor agonists on the expression of BDNF in brai

48 Administration of selective DA and 5-HT receptor agonists was also sufficient to induce pMe

49 ior hypothalamus (AH) and the interaction of 5-HT receptor agonists with arginine vasopressin (AVP) i

50 3.5 nmol), we found that the directly acting 5-HT receptor agonists, 1-[3-(trifluoromethyl)phenyl]pip

51 ons after activation by 5-hydroxytryptamine (5-HT) receptor agonists.

52 5-ht(5A) is among the recently cloned, novel 5-HT receptors and currently under investigation to iden

53 lating SCN circadian rhythm by activation of 5-HT receptors and opening of a potassium channel.

54 100beta, we investigated the codependence of 5-HT receptors and SERT in regulating S100A4/Mts1 in hum

55 ctivation of spinal excitatory amino acid or 5-HT receptors and that concomitant activation of spinal

56 stimulates smooth muscle cell growth through 5-HT receptors and the 5-HT transporter (5-HTT), and has

57 hanges in the regional density of binding to 5-HT receptors and transporters and the levels of trypto

58 tor (5-HT7R) is the most recently discovered 5-HT receptor, and its physiologic and possible pathophy

59 Serotonin (5-HT) receptor antagonism did not contribute to proprano

60 Pretreatment with a 5-HT receptor antagonist partially inhibited IL-6 increa

61 nhibitor (SSRI), or 2 microM methiothepin, a 5-HT receptor antagonist, increased microdialysate conce

62 tified the serotonin (5-hydroxytryptamine or 5-HT) receptor antagonist metitepine as a potent anorect

63 taken orally every 8 h; any first-generation 5-HT-receptor antagonist (except palonosetron) taken as

64 eceive doxorubicin were given a short-acting 5-HT-receptor antagonist and dexamethasone before doxoru

65 We aimed to assess whether a 5-HT-receptor antagonist was more effective than was pro

66 5-HT receptor antagonists (SDZ205-557, granisetron, meth

67 We conclude that PAF and 5-HT receptor antagonists accelerate DNA repair caused b

68 5-HT receptor antagonists and agonists were given as dru

69 Various 5-HT receptor antagonists inhibited cAMP production indu

70 Injecting PAF and 5-HT receptor antagonists into UV-irradiated Xeroderma p

71 The 5-HT receptor antagonists metergoline (non-specific rece

72 gonists but is inhibited by the metabotropic 5-HT receptor antagonists mianserin and methiothepin.

73 ed DNA synthesis, was accelerated by PAF and 5-HT receptor antagonists.

74 in UV-irradiated mice injected with PAF and 5-HT receptor antagonists.

75 8-oxo-deoxyguanosine was reduced by PAF and 5-HT receptor antagonists.

76 telet-activating factor (PAF) and serotonin (5-HT) receptor antagonists, regulate DNA repair.

77 Psychotropic drugs, 5-hydroxytryptamine (5-HT)-receptor antagonists, peppermint oil, and Chinese

78 ), as did 179 (79%) of 226 patients assigned 5-HT-receptor antagonists (3.29 [3.09-3.48]) and 179 (82

79 less delayed nausea than did those allocated 5-HT-receptor antagonists (p=0.05, t test) and those all

80 Attenuation of 5-HT binding by 5-HT-receptor antagonists and 5-HT-uptake inhibitors doe

81 Short-acting 5-HT-receptor antagonists are no better than is prochlor

82 Evidence for the efficacy of 5-HT-receptor antagonists seems favorable, although more

83 Because none of these 5-HT receptors appear to be expressed in the ASH sensory

84 In summary, all three 5-HT receptors are equally represented in Vg and the DRG

85 tropic and metabotropic 5-hydroxytryptamine (5-HT) receptors are expressed on whisker Abeta-afferent

86 Because dopamine (DA) and serotonin (5-HT) receptors are implicated in impulsive behavior, se

87 y 5-HT(2A)Rs and 5-HT(2C)Rs implicates these 5-HT receptors as important in the behavioral outcomes o

88 m facilitation and require the activation of 5-HT receptors at multiple sites.

89 Previously, abnormalities in 5-HT receptor binding in the medullae of infants dying f

90 A significant reduction in 5-HT receptor binding measured with 3H-LSD was observed

91 rmalities of serotonin (5-hydroxytryptamine [5-HT]) receptor binding in regions of the medulla oblong

92 nteric artery that follows the activation of 5-HT receptors, but not alpha 1-receptors, involves phos

93 at concomitant activation of spinal NMDA and 5-HT receptors can act synergistically to markedly incre

94 that combinatorial signaling through DA and 5-HT receptors can regulate the brain region- and cell-t

95 l and some clinical evidence that effects on 5-HT receptors contribute to the low risk of producing e

96 we examined the developmental regulation of 5-HT receptors controlling the excitability of pyramidal

97 g effects of serotonin, mediated by distinct 5-HT receptors, could explain why drugs targeting seroto

98 This study also shows that different 5-HT receptors coupled to these proteins can show a wide

99 episodes of enhanced 5-HT release leading to 5-HT receptor desensitization.

100 d characterized a deregulation of prefrontal 5-HT receptor electrophysiological signaling in mouse mo

101 Activation of specific 5-HT receptors evokes distinct, but highly interacting,

102 study therefore provides a detailed atlas of 5-HT receptor expression within a well-characterized neu

103 integrated activity of at least 3 different 5-HT receptor families.

104 the most recently identified members of the 5-HT receptor family, and dendritic cells express this r

105 ocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist

106 ide spectrum of human physiology through the 5-HT receptor family.

107 However, modification of 5-HT receptors following complete spinal cord injury res

108 indicate that dimerization is essential for 5-HT receptor function.

109 binding with varying changes in postsynaptic 5-HT receptor function.

110 Differences in certain 5-HT receptor functions may explain some of the clinical

111 trate that these ionotropic and metabotropic 5-HT receptors have a synergistic effect that is critica

112 Four distinct 5-HT receptors have been partially characterized, but li

113 esponses but the differing roles of the many 5-HT receptors have not been thoroughly investigated.

114 The 5-HT receptor immunolabeling was cytoplasmic, as with th

115 d that m-CPP did not appear to act through a 5-HT receptor in depressing neuronal function in the inv

116 osely match the affinity for the predominant 5-HT receptor in each region.

117 Our findings suggest the presence of a 5-HT receptor in mammalian salivary glands coupled to th

118 knowledge combinational action of SERT and a 5-HT receptor in SMC growth and Rho A/ROCK participation

119 ceptors suggested the presence of mRNA for a 5-HT receptor in these cells.

120 s 5-HT, confirming that MOD-1 functions as a 5-HT receptor in vivo.

121 repertoire of electrophysiologically active 5-HT receptors in prefrontal cortex is developmentally r

122 and alterations in the expression of several 5-HT receptors in the cortex, hippocampus, and hypothala

123 Our results indicate that post-synaptic 5-HT receptors in the developing hippocampus and cortex

124 udies, they support the presence of multiple 5-HT receptors in the mammalian retina and suggest that

125 HT receptors but is an intrinsic property of 5-HT receptors in vitro and ex vivo.

126 elinating rat Schwann cells normally express 5-HT receptors in vivo, and that receptor expression is

127 d reactivation of human 5-hydroxytryptamine (5-HT) receptors in a recombinant cell line.

128 nits form functional ligand-gated serotonin (5-HT) receptors in heterologous expression systems, it h

129 Among all described serotonin (5-HT) receptors in mammals, the type three (5-HT3) is th

130 00A10), a multifunctional protein binding to 5-HT receptors, in layer II/III neurons of the prelimbic

131 HT6 receptors are involved, along with other 5-HT receptors, in the pathophysiology and pharmacothera

132 y and depression are mediated by a number of 5-HT receptors, including autoreceptors that act to inhi

133 f the serotonin transporter and a variety of 5-HT receptors, including the 5-HT type-3 (5-HT3) recept

134 d, we demonstrate that, although presynaptic 5-HT receptors inhibit evoked neurotransmitter release f

135 Serotonin (5-HT) receptor interaction in the control of female rat

136 presence of a QD tag does not interfere with 5-HT receptor internalization or endosomal recycling.

137 adian activity rhythm; and (3) activation of 5-HT receptors is necessary for this DRN-stimulated circ

138 ing ChIs from the vSt by acting on different 5-HT receptor isoforms.

139 Of the 5-HT receptors known to be involved in proliferation, 5-

140 5-HT receptor labeling was observed in Schwann cells of

141 Serotonin (5-hydroxytryptamine; 5-HT) receptor ligands were used to assess agonist-stimu

142 This diverse action on 5-HT receptors may contribute to significant differences

143 ation of cAMP by different classes of DA and 5-HT receptors may contribute to the cell-type specifici

144 Serotonin (5-hydroxytryptamine, or 5-HT) receptors mediate a plethora of physiological phen

145 injection of 5-HT antagonists, indicating a 5-HT receptor-mediated pathway from the DRN to the SCN.

146 We show that 5-HT receptor-mediated presynaptic inhibition, at this s

147 in terms of the relative potency of 5-HT at 5-HT receptors mediating inhibition and facilitation of

148 etic outflow in a number of species, but the 5-HT receptors mediating these effects have yet to be fu

149 IL-4, IL-13, and 5-HT receptor messenger RNA expressions were determined

150 Expression of 5-HT receptor mRNA was investigated in muscle strips, in

151 st affinity for several other populations of 5-HT receptors, notably h5-HT(1A) (K(i) = 170 nM), h5-HT

152 Because serotonergic interventions alter 5-HT receptor number in the hypothalamus, we asked wheth

153 mice, suggesting that the surface delineated 5-HT receptor on platelets may promote CMAH catalytic ac

154 are direct and are mediated via postsynaptic 5-HT receptors on motoneurons.

155 here has been no anatomical demonstration of 5-HT receptors on peripheral primary afferent processes.

156 Loss of serotonin (5-hydroxytryptamine [5-HT]) receptors or of the serotonin transporter (SERT)

157 This review provides an overview of 5-HT receptor pharmacology and discusses two recent 5-HT

158 mitigating neurodevelopmental adaptations in 5-HT receptors plus compensatory alterations in 5-HT syn

159 will ultimately depend on the nature of the 5-HT receptors present over different parts of the posts

160 nal stimulation with agonists at subtypes of 5-HT receptors produces a beneficial interaction with tr

161 Previous studies showed that brainstem 5-HT receptor protein expression was abnormal in DBA/2 m

162 Therefore, expression of 5-HT receptor proteins in the medial-caudal brainstem of

163 crophages expressed the 5-HT transporter and 5-HT receptors (R) 2a, 2b, but not 2c.

164 resses 5-HT2A receptors (5-HT2ARs) and other 5-HT receptors, raising the possibility that the striata

165 gen psilocybin activates multiple serotonin (5-HT) receptors, recent evidence suggests that activatio

166 EB that are reversible by Gs protein-coupled 5-HT receptors responding to raphe-spinal activity, alth

167 .0microg), or received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1mug

168 ibit egg laying in a manner dependent on the 5-HT receptor SER-1 and the G protein GOA-1.

169 We identified that two G-protein-coupled 5-HT receptors, SER-7 and SER-5, antagonistically regula

170 ceptor, OCTR-1, and a 5-HT1A-like serotonin (5-HT) receptor, SER-4, that involves a complex interacti

171 ent Na+ channels are one potential target of 5-HT receptor signaling that have wide-ranging effects o

172 5-hydroxytryptamine (5-HT) receptor signaling potently inhibits excitatory po

173 The effect of 5-HT receptor-specific agonists and antagonists was exam

174 pirone is the 5-HT1A receptor, than the same 5-HT receptor sub-type at different locations (brain, ra

175 incipal cells via activation of two distinct 5-HT receptor subfamilies, 5-HT2A/2CR (5-HT2A/2C recepto

176 In contrast, 5 did not alter levels of any 5-HT receptor subtype in any brain region examined.

177 of this study was to further identify which 5-HT receptor subtype mediates the enterostatin feeding

178 ceptor pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pi

179 WAY-100635, an antagonist of the serotonin (5-HT) receptor subtype 5-HT1A were prepared.

180 We mapped binding at 5-HT receptor subtypes and transporters using quantitati

181 Multiple 5-HT receptor subtypes are expressed in the CA3 region o

182 Whether other 5-HT receptor subtypes are involved in the aetiology of

183 ly efficacious drugs that selectively target 5-HT receptor subtypes has been only occasionally succes

184 nally specific changes in binding to certain 5-HT receptor subtypes in obesity induced by voluntary o

185 This indicates that multiple 5-HT receptor subtypes in substantia nigra may contribut

186 ites, decreases food intake but the specific 5-HT receptor subtypes involved are controversial.

187 l raphe nucleus (DRN) and to determine which 5-HT receptor subtypes mediate these effects.

188 se to application of 5-HT, suggests that the 5-HT receptor subtypes on the motor neurons are analogou

189 Understanding the interactions between 5-HT receptor subtypes should lead to novel insights int

190 ne; however, the contributions of individual 5-HT receptor subtypes to the regulation of cocaine resp

191 Activation of different 5-HT receptor subtypes, specifically 5-HT(2) versus 5-HT

192 efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR

193 cells, reflecting the activation of distinct 5-HT receptor subtypes.

194 the presence of various ligands specific for 5-HT receptor subtypes.

195 uently due to nonspecific actions on various 5-HT receptor subtypes.

196 ansmission as a consequence of the number of 5-HT receptor subtypes.

197 Abnormalities of serotonin (5-HT) receptor subtypes have been observed in the postmo

198 sses several serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes, including the 5-HT(1A) and 5-HT

199 Thus, mCPP interacts with distinct 5-HT receptor targets that produce opposing effects on l

200 b, had significantly higher affinity for the 5-HT receptors tested than did the benzodihydrofuran-con

201 er, the precise neural pathways and specific 5-HT receptors that account for its anorectic effect hav

202 Previously, four 5-HT receptors that contributed to the 5-HT modulation o

203 ) receptor is one of 14 different serotonin (5-HT) receptors that control neural function and behavio

204 ugh both quipazine and TFMPP act on multiple 5-HT receptors, they overlap in their agonist action at

205 Furthermore, the ability of the activated 5-HT receptors to couple InsP3 synthesis was significant

206 f individual serotonin (5-hydroxytryptamine; 5-HT) receptors to mood control, we have used homologous

207 n nucleus, activation of a common serotonin (5-HT) receptor type, the 5-HT 1A receptor, depresses aud

208 of sensory afferent polarity may involve two 5-HT receptor types and that nociceptive and non-nocicep

209 .63 nM) and >300-fold selectivity over other 5-HT receptor types.

210 le groups of serotonin (5-hydroxytryptamine, 5-HT) receptors using single quantum dot (QD) probes and

211 he current investigation, desensitization of 5-HT receptors was demonstrated to inhibit the peristalt

212 Focusing on adrenergic (AR) and serotonin (5-HT) receptors, we found that adrenoceptor alpha 2C (Ad

213 Although multiple 5-HT receptors were coexpressed in PFC pyramidal neurons

214 onal networks (HNNs) endogenously expressing 5-HT receptors were employed as sensing elements to buil

215 Ligands of diverse 5-HT receptors were used to identify signaling pathway(s

216 In particular, serotonin (5-HT) receptors were shown to homodimerize and heterodim

217 signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are relatively unbiased at

218 In contrast, stimulation of 5-HT receptors with EMD 386088 caused a dose-dependent i

219 binds to the serotonin [5-hydroxytryptamine (5-HT)] receptor with relatively high affinity (Kd = 4.6

220 ird ventricle (AV3V) region, an area rich in 5-HT receptors, would attenuate increases in blood press